Janet Wittes hulumtuese
Wittes, Janet T.
Wittes, Janet Turk
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 271843772 (Personal)
Permalink: http://viaf.org/viaf/271843772
Preferred Forms
-
100 0 _
‡a
Janet Wittes
‡c
hulumtuese
-
100 1 _ ‡a Wittes, Janet T.
-
100 1 _ ‡a Wittes, Janet T. (sparse)
-
100 1 _ ‡a Wittes, Janet T.
-
100 1 _
‡a
Wittes, Janet T.
-
100 1 _
‡a
Wittes, Janet Turk
-
100 1 _ ‡a Wittes, Janet Turk
-
100 1 _
‡a
Wittes, Janet Turk
-
100 1 _ ‡a Wittes, Janet Turk
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
- 551 _ _
‡a
Statistics Collaborative, Washington, DC
Works
| Title | Sources |
|---|---|
| Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies |
|
| Assessing correlates of protection in vaccine trials |
|
| Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. |
|
| Bias and trials stopped early for benefit. |
|
| Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya |
|
| Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval |
|
| Clinical trials must cope better with multiplicity |
|
| Comment on paper by Crowe et al. |
|
| Commentary on 'Measurement in clinical trials: a neglected issue for statisticians?'. |
|
| Commentary on Randomization: The forgotten component of the randomized clinical trial |
|
| Comments on the FDA Draft Guidance on Adaptive Designs |
|
| Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) |
|
| Correlates, surrogates, and vaccines. |
|
| Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial |
|
| The data monitoring experience in the MOXCON trial |
|
| Discussion of Paper by Korn and Freidlin |
|
| Ecology, pollution, environment |
|
| Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure |
|
| Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. |
|
| Environmental science |
|
| Experience collecting interim data on mortality: an example from the RALES study |
|
| The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations |
|
| First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. |
|
| Forming your phase III trial's data and safety monitoring board: a perspective on safety |
|
| Immunity to influenza in older adults with chronic obstructive pulmonary disease |
|
| Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination |
|
| The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. |
|
| Jerome Cornfield's contributions to early large randomized clinical trials and some reminiscences from the years of the slippery doorknobs |
|
| Letter from the DSMC regarding a clinical trial of lutein in patients with retinitis pigmentosa |
|
| Linear Rank Tests for Survival Data: Equivalence of Two Formulations |
|
| Missing inaction: preventing missing outcome data in randomized clinical trials |
|
| Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial |
|
| New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval |
|
| On changing a long-term clinical trial midstream |
|
| On independent data monitoring committees in oncology clinical trials |
|
| On looking at subgroups |
|
| Outcome measures to assess efficacy of treatments for age-related macular degeneration |
|
| Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop |
|
| Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors |
|
| Pazopanib versus sunitinib in renal cancer |
|
| Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya |
|
| Playing safe and preserving integrity: making the FDA model work. |
|
| Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques |
|
| A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. |
|
| Remembrances of Max Halperin |
|
| Response to Letter Regarding Article, “Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas” |
|
| Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region |
|
| Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl |
|
| Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children |
|
| Sample size calculations for randomized controlled trials. |
|
| Some practical problems in implementing randomization. |
|
| Statistical monitoring of clinical trials : a unified approach |
|
| Stopping a trial early - and then what? |
|
| Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease |
|
| Thoughts on A.B. Hill's Watson Lecture |
|
| Times to event: why are they hard to visualize? |
|
| Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. |
|
| Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory |
|
| The treatment of missing data in a large cardiovascular clinical outcomes study |
|
| University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion). |
|
| Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline |
|
| The Use of Interim Analysis for Sample Size Adjustment |
|
| What information should a sponsor of a randomized trial receive during its conduct? |
|
